Thursday, January 21, 2021 Daily Archives

Sheer magnetism: Gamma Biosciences to acquire BioMagnetic Solutions

by

Gamma Biosciences will buy cell selection and bioseparation company BioMagnetic Solutions to support development for advanced therapies. Funded by investment firm KKR, Gamma Biosciences is a growing portfolio of life science tools companies. The latest acquisition of BioMagnetic Solutions provides access to various resources and support needed to develop and commercialize X-GRAFFE, an immunomagnetic cell selection system based on the principle of using antibodies or other affinity ligands attached to magnetic particles. “When the antibody binds to a target (e.g.…

January 21, 2021

Oxford vaccine fill-finish site threatened by severe floods

by

Wockhardt is operating as normal to supply AstraZeneca’s COVID-19 vaccine after being hit by a storm at its Wrexham, Wales, fill-finish facility. Storm Christoph has caused – and continues to cause – severe damage across North Wales, and yesterday hit a facility producing the Oxford-AstraZeneca vaccine (AZD1222) run by Wockhardt UK. “Last night at approximately 1600 hours, Wockhardt UK experienced mild flooding, resulting in excess water surrounding part of the buildings across site,†the third-party manufacturer said in a statement.…

January 21, 2021

Regeneron confident it can scale-up to meet US COVID MAb demands

by

Regeneron has entered an agreement worth $2.625 billion with the US government and believes it can supply 1.25 million additional doses of its monoclonal antibody cocktail for COVID-19.   The US Department of Health and Human Services (HHS)and the Department of Defense (DOD) will purchase finished doses of the antibody cocktail, REGN-COV2, a combination of casirivimab and imdevimab by June as part of Operation Warp Speed (OWS). The new agreement comes after the Biomedical Advanced Research and Development Authority (BARDA)  granted Regeneron…

January 21, 2021